グルクロン酸トリメトレキサート
グルクロン酸トリメトレキサート · CI 898 dihydrochloride · CI 898 TRIHYDROCHLORIDE · Trimetrexate glucuronate · CI 898 D-Glucuronic Acid Salt (Trimetrexate D-Glucuronic Acid Salt) · 5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]quinazoline-2,4-diamine D-glucuronate · 5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediaminetrihydrochloride
識別子と物理属性
| CAS No. | 82952-64-5 |
|---|---|
| 分子式 | C25H33N5O10 |
| 平均分子量 | 563.6 g/mol |
| 単同位体質量 | 563.22274227 g/mol |
| SMILES | COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(=O)O |
| InChIKey | ZCJXQWYMBJYJNB-LRDBBFHQSA-N |
| PubChem CID | 54949 |
| ChEMBL | CHEMBL2218878 |
| EC No. | 692-446-3 |
| DTXSID | DTXSID90273968 |
| 現地名 | グルクロン酸トリメトレキサート |
化学・物理的性質
| 極性表面積 | 253 |
|---|---|
| 水素結合供与体数 | 8 |
| 水素結合受容体数 | 15 |
| 回転可能結合数 | 11 |
| 重原子数 | 40 |
| 形式電荷 | 0 |
| 複雑度 | 648 |
| Human Drugs | FDA approved drugs -> Active ingredient |
| 貯蔵条件 | Store at -20°C |
| 外観・状態 | Solid |
| 色 | Off-white to light yellow |
安全性と法規制
| GHS 分類 | WarningH361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]P203, P280, P318, P405, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. |
|---|---|
| 規制情報 | Hazard Traits - Developmental Toxicity |
| Hazard Classes and Categories | Repr. 2 (100%) |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Trimetrexate glucuronateAmbiguous-DILI-concern3Warnings & precautionsDOI:10.1016/j.drudis.2016.02.015 |
| 危険有害性情報 | コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H361 |
用途
説明
Trimetrexate glucuronate is a nonclassical antifolate introduced in the U.S.A. and Canada as second-line therapy for the treatment of Pneumocystis carinii pneumonia (PCP) and toxoplasmosis in AIDS patients who are refractory or intolerant to co-trimoxazole therapy. Trimetrexate glucuronate is reportedly to be in clinical trials for the treatment of several types of cancer including colorectal, gastric, pancreas, prostate, bladder, lung, breast, head, and neck cancers. It is also in early clinical trials for topical use in treating psoriasis and as an oral drug to treat rheumatoid arthritis. The mechanism of action of trimetrexate glucuronate is via inhibition of the enzyme dihydrofolate reductase which mediates the reduction of dihydrofolate to tetrahydrofolic acid and results in disruption of DNA, RNA and protein synthesis, with consequent cell death. Due to its toxicity to bone marrow and the GI tract, trimetrexate glucuronate must be concurrently administered with leucovorin as a rescue agent.
使用
Antineoplastic.